The Life Sciences Law Firm Index identifies the most active and relevant firms for life science companies.
Still recovering from a market correction two years ago, and with a scarcity of attractive targets and ongoing macroeconomic uncertainty, the life sciences dealmaking space is in a state of flux.
Last year proved a slow one for dealmaking in the life sciences space. But that didn’t stop two of the major legal players in it from consummating one themselves: In November, Arnold & Porter and Kaye Scholer agreed to merge, bringing together two formidable healthcare practices...
It’s time to know more about corporate venture capital because, unlike traditional venture or angel groups, there’s much less insight on corporate VCs and their practices.
If only the Pied Piper boys had known about litigation finance.
About a month ago, I discussed the venture capital landscape, and why litigation funders are attractive partners for VCs and VC-backed companies in need of resources to adequately defend their businesses. A similar, but distinct, phenomenon exists in private equity.